Peptide News Digest
Trend Report 12 min read

Buying Wegovy or Mounjaro Abroad: Price Gaps, Import Rules, Counterfeits and Cold Storage

South Korea now lets travelers bring home three months of weight-loss drugs, then cracked down on resale. Rules elsewhere, storage limits and fake pens.

Key points

  • Since November 12, 2026, South Korea has let travelers bring in up to six containers, or about a three-month supply, of weight-loss drugs prescribed and bought legally abroad, for their own treatment
  • On November 19, Korea's Ministry of Food and Drug Safety began a crackdown on online sales and secondhand trading; reselling or giving away drugs brought in for personal use violates the Pharmaceutical Affairs Act
  • The lowest Mounjaro dose costs about 300,000 won ($225) for four weeks in Korea, roughly three times what some Japanese clinics charge; Lilly's U.S. self-pay price for the 2.5 mg Zepbound KwikPen is $299
  • In Japan, Mounjaro is approved for type 2 diabetes, and tirzepatide for obesity is sold as Zepbound
  • The FDA says importing drugs for personal use is illegal in most circumstances; its three-month guideline is enforcement discretion, which its own manual says is not a license
  • U.S. labels allow Mounjaro and Zepbound single-dose pens up to 21 days unrefrigerated at up to 30°C (86°F), and Wegovy single-dose pens up to 28 days before the cap is removed; none may be frozen
  • Counterfeit pens found in the U.S. and UK in 2025 and 2026 carried batch numbers that also belong to genuine products

Korea's new carry-in rule and the Fukuoka math

On November 12, South Korea started letting travelers carry in weight-loss drugs such as Wegovy and Mounjaro if a doctor prescribed them abroad and they were bought legally there. The Ministry of Food and Drug Safety (MFDS) and the Korea Customs Service set the limit at six containers, which The Korea Herald described as roughly a three-month supply, for the traveler's own treatment. The drug has to be approved in the country where it was prescribed and bought. If the dosing instructions call for more than six containers, the traveler may bring up to three months' worth.

Until then, customs had held these drugs whether a traveler bought them with a prescription or ordered them from an unauthorized overseas seller. The agencies said they had received "repeated complaints from travelers whose medicines were held at customs even though they had been properly prescribed and purchased." Customs detected 1,097 unauthorized entries of Wegovy and Mounjaro from January through August 2026, more than eight times the 134 cases in all of 2025, the Herald reported.

Price explains the demand. A four-week supply of the lowest Mounjaro dose costs about 300,000 won ($225) in Korea, while some Japanese clinics charge around 100,000 won. On November 13, the day after the rule took effect, the Herald found Korean forum users comparing flights. "If I can get a cheap flight, a day trip to Fukuoka would cost about 700,000 won ($520), including airfare and a three-month supply of 5-milligram Mounjaro," one wrote. The same supply at home would cost more than 1 million won, the user said. Forum users call Mounjaro bought in Japan "sushijaro."

Lawmakers questioned the rollout the same day at a meeting of the National Assembly's Health and Welfare Committee. People Power Party Rep. Lee Man-hee asked how customs officers would judge whether drugs brought in on repeat trips were for personal use, since no system tracks what a traveler carried in before. Food and Drug Safety Minister Oh Yu-kyoung said the agencies moved fast because people had asked them to fix the problem "as soon as possible."

Mounjaro is a diabetes brand in Japan

The Herald traced the lower Japanese price to Japan's national health insurance system, which lists Mounjaro for type 2 diabetes; the paper said the listing cut its official price by 25 percent.

That label matters for a weight-loss buyer. In Japan, Mounjaro is the diabetes product. Eli Lilly Japan and Mitsubishi Tanabe Pharma sell the same molecule, tirzepatide, for obesity under a different name, Zepbound, which Japan's health ministry approved in December 2024. That approval covers adults who have not responded to diet and exercise and who also have high blood pressure, abnormal blood fats, or type 2 diabetes, and who meet body mass index (BMI) thresholds. A Korean visitor without diabetes who leaves a Japanese clinic with Mounjaro is using it outside its approved Japanese indication, even if the prescription and the purchase were legal.

Names shift from country to country. In the U.S., Lilly sells tirzepatide as Mounjaro for type 2 diabetes and as Zepbound for weight management. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the Mounjaro KwikPen in January 2024 for both type 2 diabetes and weight management. Someone on Zepbound at home may be handed Mounjaro abroad and get the same drug.

A week later, Seoul went after resale

On Thursday, November 19, the MFDS announced a nationwide crackdown on illegal online sales, brokering, and advertising of GLP-1 obesity drugs, The Korea Times reported. It covers direct purchases from overseas sellers and secondhand trading. The ministry warned that people who bring the drugs in for their own treatment violate the Pharmaceutical Affairs Act if they resell them or give them to someone else, so splitting a three-month supply with a friend is covered too. It set up a reporting center and a task force for monitoring and on-site inspections, and said it would request investigations and file criminal complaints.

The domestic market behind all this is large. Health Insurance Review and Assessment Service data cited by the Times show Mounjaro was prescribed 1,501,161 times in Korea from its August 2025 launch through May 2026, with monthly prescriptions climbing from 18,579 to 273,140. Wegovy, on sale since October 2024, was prescribed 1,228,867 times through May.

U.S. rules: a three-month guideline with no guarantee

The FDA's personal importation page is narrower than the common idea of a 90-day allowance for any medicine. It says that "in most circumstances, it is illegal for individuals to import drugs or devices into the U.S. for personal use," and that a drug approved in another country but not approved in the U.S. is illegal to import. The flat 90-day allowance on that page is for foreign nationals visiting the U.S. who bring their own medicine.

For everyone else, the agency describes enforcement discretion, meaning it may choose not to act. FDA staff "may consider a more permissive decision" for a prescription drug when it treats a serious condition for which effective treatment may not be available in the U.S., is not promoted to U.S. residents, and does not pose an unreasonable risk. The person also has to affirm in writing that it is for personal use, generally no more than a three-month supply, and either name the U.S.-licensed doctor responsible for the treatment or show that it continues treatment started abroad. The FDA's Regulatory Procedures Manual adds that this discretion "should not be interpreted as a license to individuals to bring in such shipments." Under the same manual, refused drugs valued at $2,500 or less can be destroyed by the FDA.

Wegovy, Zepbound, Ozempic, and Mounjaro are all sold in U.S. pharmacies, which sits awkwardly with the "not available domestically" condition. The FDA also says it "cannot ensure the safety and effectiveness" of medicine bought during trips outside the country and recommends buying only from legal U.S. sources.

U.S. cash prices have dropped, which narrows some of the gaps that drive these trips. On November 20, 2026, Lilly's Zepbound savings page listed $299 a month for the 2.5 mg KwikPen or four 2.5 mg vials, $399 for the 5 mg KwikPen, and $449 for 7.5 mg through 15 mg under an offer that requires each refill within 45 days. The regular prices at those higher doses are $499 to $699. Novo Nordisk lists Wegovy pens at $199 a month for new patients' first two fills of the 0.25 mg or 0.5 mg dose through December 31, 2026, then $349, or $399 for Wegovy HD 7.2 mg. The TrumpRx.gov Wegovy listing shows the same offer. The starting Mounjaro dose in Korea, at about $225, still undercuts Lilly's $299 U.S. self-pay price for the same strength, and the Japanese clinic price is lower again. Our guide to TrumpRx and the 2026 GLP-1 price cuts and our international price comparison cover the numbers in more detail.

Canada's generics and Mexico's fake-pen alerts

Canada's draw is generic semaglutide. Pharmacies told CBC News in late May 2026 that generics from Apotex and Dr. Reddy's Laboratories had cut the price to roughly C$100 a month. In the U.S., the FDA's drug approval database lists Apotex's generic semaglutide application with tentative approval as of April 7, 2026. Tentative approval is the status the FDA gives a generic that meets its standards but cannot yet be sold because of patents or exclusivity, so there is no FDA-approved generic semaglutide to fill at a U.S. pharmacy.

Canadian provinces can restrict sales to visitors, and British Columbia has. When it restricted sales in April 2023, the province said B.C. pharmacies had filled 15,798 Ozempic prescriptions for U.S. residents in January and February of that year, 13,197 of them at two internet pharmacies. Under rules widened in July 2025 to include tirzepatide and dulaglutide, B.C. pharmacists cannot sell these drugs to people who are neither Canadian citizens nor permanent residents unless they are in the pharmacy in person with a prescription signed by a Canadian doctor or nurse practitioner. That rule is British Columbia's; other provinces set their own.

Mexico requires a prescription for Ozempic under Article 226 of its General Health Law, according to the federal health regulator, COFEPRIS. The agency has issued at least two alerts this year about fake Ozempic found in Mexico. In March it flagged counterfeit 1 mg pens whose main giveaway was labeling in languages other than Spanish. In May it flagged lot PP5K617 of the 0.25 mg to 0.5 mg pen, whose device differed from Novo Nordisk's FlexTouch design. COFEPRIS tells buyers to avoid medicines sold online, at street markets, at prices far below the market, or with labels in a language other than Spanish.

We looked for reporting by an established news outlet on Americans buying GLP-1 drugs in Mexican border pharmacies that we could read in full and did not find one, so this article leaves out the Mexican price figures that circulate on clinic and pharmacy marketing sites.

Britain's warnings and Australia's three-month exemption

The MHRA's summer warning on July 24, 2026 ended with a rule of thumb. Andy Morling, head of the agency's Criminal Enforcement Unit, said the "simple rule for staying safe" is that anyone offered a GLP-1 medicine without needing a prescription should "walk away." The MHRA noted that GLP-1 medicines authorized in the UK have been shown safe and effective only for people with a BMI of 27 or more, and that fake products can be contaminated.

A pharmacy counter has not always been a safe filter either. In February 2026, the MHRA contacted patients who might have received fake Mounjaro KwikPen 15 mg pens from The Private Pharmacy Clinic in Birmingham. The fakes carried batch number D873576, a genuine batch number for the 7.5 mg pen. Testing found tirzepatide in them, but the agency could not confirm the contents were sterile.

Lilly has since gone to court. City AM reported on November 6 that the company filed a case in the English High Court naming BT, EE, Plusnet, Sky, TalkTalk, and Virgin Media, the route English law requires for blocking offshore sites that sell counterfeit goods. "What is being sold on these websites is not a medicine," a Lilly spokesperson told the paper. In May, the court had granted its first blocking order for medicines, covering sites selling counterfeit and unlicensed versions of Novo Nordisk's semaglutide.

Australia's Therapeutic Goods Administration (TGA) has a traveller's exemption for medicines carried into the country. It covers medicine for your own use or for an immediate family member traveling with you, and it comes with conditions:

  • Do not sell or supply the medicine to anyone else.
  • Keep it in the original packaging, with dispensing labels if possible.
  • For prescription medicines, carry the prescription or a doctor's letter stating what you take and how much you are bringing.
  • Bring no more than a three-month supply.
  • Take any leftovers with you when you leave Australia.

The TGA's own worked example is a traveler with diabetes who carried his insulin in its original packaging, with his prescription and a doctor's letter, in a small cooler on board. Medicines mailed into Australia fall under a separate Personal Importation Scheme with its own rules, which our guide to peptide laws in Australia, New Zealand, the UK, Malaysia, and Thailand explains.

How long each pen can stay out of the fridge

Korean officials and medical experts raised storage concerns when the carry-in rule was announced. The Herald noted that injectable obesity drugs generally need refrigerated transport and that poor handling could make them less effective or raise safety risks. The current U.S. labels set these limits:

Product (U.S. label)Before useTime allowed out of the refrigerator
Wegovy single-dose penRefrigerate at 2°C to 8°C (36°F to 46°F)Up to 28 days at 8°C to 30°C (46°F to 86°F), only before the cap is removed
Wegovy FlexTouch pen (4 weekly doses)Refrigerate before first useAfter first use, 56 days at 15°C to 30°C (59°F to 86°F) or in the refrigerator
Ozempic penRefrigerate before first useAfter first use, 56 days at 15°C to 30°C or in the refrigerator
Mounjaro or Zepbound single-dose pen or vialRefrigerateUp to 21 days total at no more than 30°C (86°F)
Mounjaro or Zepbound KwikPen or multi-dose vialRefrigerateUnopened, 30 days at room temperature up to 30°C; once opened, discard after 30 days or 4 weekly doses

None of these may be frozen, and all should be kept from heat and light. The Wegovy patient instructions say to throw a single-dose pen away if it has been exposed to temperatures above 30°C (86°F).

A Fukuoka day trip fits easily inside those windows. A summer trip, a long layover, or a three-month supply carried home on one flight leaves less margin, because the clock on single-dose pens keeps running once they leave the cold. Pens sold in other countries come with their own leaflets, and their limits can differ from the U.S. versions, so the leaflet in the box is the one to read.

Same drug, unfamiliar pen

A pen bought abroad may not look like the one a U.S. pharmacist hands over, which makes a fake harder to spot. In the U.S., Mounjaro and Zepbound now come as cartons of four single-dose pens, single-dose vials, multi-dose vials, or a single-patient-use KwikPen holding four weekly doses. The UK's Mounjaro KwikPen also holds four doses, at 2.5 mg to 15 mg per dose. Japan's Zepbound uses a single-use autoinjector called Ateos.

Multi-dose pens state their contents in two ways. The U.S. Wegovy FlexTouch label lists 9.6 mg in 3 mL, which is four weekly doses of 2.4 mg. A starter Ozempic pen holds 2 mg in total and delivers 0.25 mg or 0.5 mg doses. Someone switching between formats needs the dose per injection, and the larger number on the carton is not it.

Familiar packaging does not prove a pen is real. The FDA's December 2025 warning about counterfeit Ozempic 1 mg pens found in the legitimate U.S. supply chain noted that the fake lot number, PAR1229, also belongs to authentic product; the visible difference was where the "EXP/LOT" text sat on the label. In the UK case above, the fake 15 mg pens used a real 7.5 mg batch number. In December 2023, the FDA found that needles packaged with seized counterfeit Ozempic were themselves fake, so their sterility could not be confirmed. Our guide to fake Ozempic and Mounjaro goes through the checks for a pen in hand.

The prescription does not travel with the pen

Every system described here assumes a prescriber. Korea's rule applies to drugs prescribed abroad, the FDA's discretion asks for the name of a U.S.-licensed doctor or proof of treatment begun overseas, and the TGA expects a prescription or a doctor's letter. None of them supply follow-up care at home.

That gap shows up in dosing. According to the MHRA's description of the KwikPen approval, tirzepatide starts at 2.5 mg once a week for four weeks, then rises to 5 mg, and a doctor may raise it further in steps at least four weeks apart, up to 15 mg. A three-month supply of a single strength, bought on one trip, leaves no way to change the dose for about 12 weeks without buying again. If side effects or questions come up, the prescriber may be in another country. Side effects can be reported to the FDA through MedWatch in the U.S. and through the MHRA's Yellow Card scheme in the UK.

Sharing is the other line these rules draw. Korea now treats giving the drugs away as a violation of the Pharmaceutical Affairs Act, and Australia's exemption bars supplying them to anyone else. The U.S. Ozempic label adds a medical reason for multi-dose pens: one "must never be shared between patients, even if the needle is changed."

Updates and corrections

No corrections yet.

Limitations

  • Korean and Japanese prices come from news reports citing clinics and forum users, not official price lists, and they vary by clinic and exchange rate
  • We found no full-text news investigation of Americans buying GLP-1 drugs in Mexico, so the Mexico section relies on COFEPRIS alerts as reported by Mexican outlets
  • The TGA website did not load during research; the traveller's exemption conditions come from an archived copy of the TGA page captured November 22, 2025
  • Storage limits are from current U.S. labels; pens sold in other countries carry their own labels, which may differ
  • Import rules can change quickly; Korea's carry-in rule took effect one day after it was announced
  • This article describes published rules and risks and is not legal or medical advice

Citations

  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
    Personal Importation
    regulatory 2025
  7. 7.
  8. 8.
  9. 9.
  10. 10.
  11. 11.
  12. 12.
  13. 13.
  14. 14.
  15. 15.
  16. 16.
  17. 17.
  18. 18.
  19. 19.
  20. 20.
  21. 21.
  22. 22.
  23. 23.
  24. 24.
  25. 25.

Peptides in this article

Full peptide profiles with evidence levels, dosing data, and safety notes live on peptidelist.org.

Related insights